Below are the most recent publications written about "Cytoreduction Surgical Procedures" by people in Profiles.
-
Moore KN, Bookman M, Sehouli J, Miller A, Anderson C, Scambia G, Myers T, Taskiran C, Robison K, M?enp?? J, Willmott L, Colombo N, Thomes-Pepin J, Liontos M, Gold MA, Garcia Y, Sharma SK, Darus CJ, Aghajanian C, Okamoto A, Wu X, Safin R, Wu F, Molinero L, Maiya V, Khor VK, Lin YG, Pignata S. Atezolizumab, Bevacizumab, and Chemotherapy for Newly Diagnosed Stage III or IV Ovarian Cancer: Placebo-Controlled Randomized Phase III Trial (IMagyn050/GOG 3015/ENGOT-OV39). J Clin Oncol. 2021 06 10; 39(17):1842-1855.
-
Chouliaras K, Senehi R, Ethun CG, Poultsides G, Tran T, Grignol V, Gamblin TC, Roggin KK, Tseng J, Fields RC, Weber SM, Russell GB, Levine EA, Cardona K, Votanopoulos K. Recurrence patterns after resection of retroperitoneal sarcomas: An eight-institution study from the US Sarcoma Collaborative. J Surg Oncol. 2019 Sep; 120(3):340-347.
-
Zaidi MY, Ethun CG, Liu Y, Poultsides G, Howard JH, Mogal H, Tseng J, Votanopoulos K, Fields RC, Cardona K. The impact of unplanned excisions of truncal/extremity soft tissue sarcomas: A multi-institutional propensity score analysis from the US Sarcoma Collaborative. J Surg Oncol. 2019 Sep; 120(3):332-339.
-
Trieu V, Aulet RM, Ciolino A, Rimash T. SMARCB1-Deficient Sinonasal Carcinoma: A Case Report and Discussion of the Clinical Implications. Ann Otol Rhinol Laryngol. 2019 Jul; 128(7):676-680.
-
Massari F, Di Nunno V, Santoni M, Gatto L, Mollica V, Porta C. Re: Bimal Bhindi, E. Jason Abel, Laurence Albiges, et al. Systematic Review of the Role of Cytoreductive Nephrectomy in the Targeted Therapy Era and Beyond: An Individualized Approach to Metastatic Renal Cell Carcinoma. Eur Urol 2019;75:111-28: Cytoreductive Nephrectomy in the Targeted Therapy Era: This is Not the End. Eur Urol Oncol. 2019 09; 2(5):603-604.
-
Hendrix RJ, Damle A, Williams C, Harris A, Spanakis S, Lambert DH, Lambert LA. Restrictive Intraoperative Fluid Therapy is Associated with Decreased Morbidity and Length of Stay Following Hyperthermic Intraperitoneal Chemoperfusion. Ann Surg Oncol. 2019 Feb; 26(2):490-496.
-
Massari F, Di Nunno V, Gatto L, Santoni M, Schiavina R, Cosmai L, Brunocilla E, Ardizzoni A, Porta C. Should CARMENA Really Change our Attitude Towards Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma? A Systematic Review and Meta-Analysis Evaluating Cytoreductive Nephrectomy in the Era of Targeted Therapy. Target Oncol. 2018 12; 13(6):705-714.
-
Massari F, Di Nunno V, Santoni M. Re: Arnaud M?jean, Alain Ravaud, Simon Thezenas, et al. Sunitinib Alone or After Nephrectomy in Metastatic Renal-cell Carcinoma. N Engl J Med 2018;379:417-27: CARMENA Trial: Is This the End of Cytoreductive Nephrectomy in Patients with Clear-cell Renal Cell Carcinoma? Eur Urol Oncol. 2019 05; 2(3):340-341.
-
Mosillo C, Ciccarese C, Bimbatti D, Fantinel E, Volta AD, Bisogno I, Zampiva I, Santoni M, Massari F, Brunelli M, Montironi R, Tortora G, Iacovelli R. Renal cell carcinoma in one year: Going inside the news of 2017 - A report of the main advances in RCC cancer research. Cancer Treat Rev. 2018 Jun; 67:29-33.
-
Edmund L, Rotker KL, Lakis NS, Brito JM, Lepe M, Lombardo KA, Renzulli JF, Matoso A. Upgrading and upstaging at radical prostatectomy in the post-prostate-specific antigen screening era: an effect of delayed diagnosis or a shift in patient selection? Hum Pathol. 2017 01; 59:87-93.